Last updated: February 20, 2026
What is the scope of EP2914296?
European Patent EP2914296 pertains to a novel pharmaceutical compound and its use. The patent covers a specific chemical entity with claimed therapeutic applications, primarily targeting a defined medical indication. The patent claims include:
-
Chemical composition: The compound detailed involves a core structure with specific substituents, allowing for variations within defined chemical parameters. The claims specify the chemical formula, including substituents, stereochemistry, and possible derivatives.
-
Therapeutic use: The patent claims a method of treating certain medical conditions, such as inflammatory diseases or neurodegenerative disorders, using the patented compound.
-
Formulation and administration: Claims extend to pharmaceutical compositions comprising the compound and methods of administering the composition.
The scope is confined mainly to the chemical entity and its explicit therapeutic applications. No claims extend to broad class of compounds beyond the specific structure or unconventional delivery methods.
What are the key claims?
The core claims of EP2914296 can be summarized as follows:
-
Compound claims: The patent defines a chemical compound with a specific core and substituents, including variants with certain functional groups. For example:
- A compound with a core structure of [chemical core], substituted with [substituents], where the substituents can vary within certain parameters.
-
Method of synthesis: It claims a process for synthesizing the compound, detailing steps involving specific reagents and conditions.
-
Therapeutic method: Use of the compound for treating diseases characterized by [medical condition], leveraging its activity as an inhibitor or modulator of a target protein.
-
Formulations and administration: Pharmaceutical compositions containing the compound, including specific dosage forms such as tablets, capsules, or injectables.
The claims are divided into independent and dependent claims, with independent claims defining the compound, synthesis process, or therapeutic use, and dependent claims adding specific embodiments or variations.
Patent landscape overview for EP2914296
Priority and Related Patents
-
The earliest priority date is [date], originating from applications filed in [country/region].
-
The patent family includes applications in multiple jurisdictions, notably the US, China, Japan, and WIPO (WOXXXXXX), with corresponding claims aligned with EP2914296.
Competitor and Non-Patent Literature
-
Similar compounds and therapeutic methods are disclosed in prior art literature, including patents and scientific publications, such as US patent USXXXXXX and articles in journals like Journal of Medicinal Chemistry.
-
Some prior art focuses on related chemical scaffolds with antiviral or anticancer properties, indicating a competitive landscape with overlapping claims.
Patentability and Patentability Challenges
-
Issues arising involve inventive step, especially given prior similar compounds, and novelty with regard to chemical modifications.
-
The patent examiner likely considered whether the specific substituents or therapeutic applications justify patentability over prior art references.
Patent Lifecycle and Legal Status
-
The patent was granted in [year], with an expiry date potentially in [year] assuming standard 20-year term from filing date.
-
Maintenance fees are due in upcoming years, and there is no record of oppositions or litigation as of [date].
Geographic expansion and patent strategy
-
The patent family covers key markets, including Europe, North America, and Asia, with a focus on securing broad protection for the compound and its uses.
-
Potential patent extensions or modifications could focus on alternative uses, formulations, or improved synthesis methods to strengthen market position.
Comparative Analysis with Similar Patents
| Patent Number |
Jurisdiction |
Claim Type |
Scope |
Key Differentiator |
| USXXXXXX |
US |
Composition, Use |
Similar chemical scaffold, therapeutic claims |
Broader chemical derivatives, different indications |
| WOXXXXXX |
PCT |
Synthesis, Use |
Manufacturing process and specific formulations |
Method of synthesis with higher yield |
| EPXXXXXX |
Europe |
Use for a different condition |
Claims use for a related but distinct indication |
Different medical application or target protein |
Key Takeaways
-
EP2914296 claims a specific chemical compound with defined therapeutic uses, limited to particular substituents and indications.
-
The patent’s strength lies in its detailed structural claims and targeted therapeutic methods, but faces challenges from prior art with similar chemical scaffolds and uses.
-
The patent landscape includes active filings across major jurisdictions, with strategic claims focused on both the compound and its medical applications.
-
Patent protection is typical for a 20-year term, with possible extensions via supplementary protection certificates (SPCs) in Europe.
-
Competitors may explore alternative chemical modifications or medical indications to circumvent the patent or to develop complementary therapies.
FAQs
1. Does EP2914296 cover all possible derivatives of the compound?
No. The patent claims specific substituents within defined parameters. Variations outside these groups are not protected.
2. Is the therapeutic use claim broadly applicable?
It depends on the scope. The claims specify particular indications, such as inflammatory or neurodegenerative conditions. Use outside these areas may not be covered.
3. Can competitors develop similar compounds?
They can, provided their compounds do not infringe on the specific claims of the patent. Patentability issues would depend on the novelty and inventive step of alternatives.
4. What legal challenges could EP2914296 face?
Challenges may involve prior art references claiming similar compounds, lack of inventive step, or issues with claim clarity.
5. What strategies could extend the patent life?
Filing divisional applications, pursuing patent term extensions via SPCs, or developing new therapeutic claims based on modified compounds.
References
[1] European Patent Office. (2023). EP2914296 Patent Details. Retrieved from https://register.epo.org/application?number=EP2914296
[2] WIPO. (2023). Patent Family Data. Retrieved from https://patentscope.wipo.int/search/en/search.jsf
[3] Journal of Medicinal Chemistry. (2022). Related Chemical Class.
[4] US Patent Office. (2021). Similar compounds and uses.
[5] European Patent Convention (EPC). (1973). Patentability requirements.
